These agents are demonstrated to stimulate the immune system and improve tumor sensitivity to ICIs by inducing immunogenic cell death, enabling the release of tumor-associated antigens (TAA), and elevating PD-L1 expression on tumor cells (21–23). This evidence concerns the gene CD274 and neoplasm.